Core Viewpoint - The company is actively advancing its innovative drug pipeline, which includes both chemical and biological drugs, with several projects on track for clinical trials and regulatory approvals [1] Group 1: Innovative Drug Development - The company is focusing on key innovative drugs in the chemical field, including the brain neuroprotective agent WYY and the antithrombotic drug ZT [1] - The WYY injection for stroke indications has completed basic experiments related to IND application, with plans to submit a clinical trial application in the second half of the year [1] - The ZT project has identified candidate drugs, and the company is progressing with the research [1] Group 2: Biological Drug Initiatives - In the biological drug sector, the company is developing a second-class innovative drug, CBD, aimed at treating rare diseases such as pulmonary arterial hypertension [1] - The CBD project has initiated the preparation for the DMF filing of the raw material [1] Group 3: Collaborations and Clinical Trials - The company's affiliate, Dongfang Lue, has completed patient enrollment for the Phase III clinical trial of VGX-3100, targeting HPV-related high-grade precancerous lesions [1] - Two additional indications for treating high-grade precancerous lesions related to HPV-16 and/or HPV-18 have received approval from the National Medical Products Administration, allowing them to enter Phase II clinical trials [1]